Efficacy of COVID-19 vaccine in cancer patients is comparable to levels reported in the general population
Initial delays to antibody production are followed by similar levels of vaccine efficacy after a second vaccine dose
Some medical oncologists contemplate leaving the profession due to COVID-19
Findings from the third ESMO Resilience Task Force survey highlight the detrimental effect of long working hours and changes to clinical routine on future career plans
Molecular profiling holds promise to speed up drug development in rare tumours
Findings from several studies highlight the increasing utility of this approach to identify druggable genetic alterations
Adequate antibody response to SARS-CoV-2 vaccine in patients on chemotherapy or immunotherapy
Most, but not all, patients on chemotherapy or immunotherapy for solid tumours had an adequate immune response after two doses of mRNA-1273 vaccination, with no new safety concerns
Rare tumours make it to a Presidential Symposium
Rare tumours have been neglected for decades, with lack of funding, lack of research and lack of visibility. It is encouraging to see how this is changing and how research in rare tumours is not only taking place, but also being highlighted in Presidential Symposium 3 at this year’s ESMO Congress.
More than one in six cancer patients experience long-term effects of COVID-19
OnCOVID study reveals that respiratory symptoms, fatigue and cognitive/psychological dysfunction persist after acute Sars-CoV-2 infection, with an impact on survival and oncological outcomes after recovery
Innovation is creating new ways to support oncologists
How ESMO is transforming the challenges from the COVID-19 pandemic into opportunities to re-shape the future of the oncology community
Should we invest more in registry data?
During the COVID-19 pandemic, real-world data have shown they can support clinical decision-making in complex situations but extensive bureaucracy is still a limiting factor
Vaccinate cancer patients against COVID-19: experts address major uncertainties
At an ESMO Live Roundtable, a panel of experts discussed the benefits and risk of COVID-19 vaccination in patients with cancer, the practicalities of vaccinating those undergoing immunosuppressant treatment and the potential advantages and disadvantages of flexible dosing intervals.